|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
Mesoblast has a TR of 0.04, and an ATR(14) of 0.067.
Average true range (ATR) is a technical analysis volatility indicator originally developed by J. Welles Wilder Jr. for commodities. The indicator does not provide an indication of price trend simply the degree of price volatility.
Calculation: Average True Range (ATR):
1) Current ATR = [(Prior ATR x 13) + Current TR] / 14;
2) Where TR = max[(high-low) abs(high-close previous) abs (low-close previous)]
PROFILE: Mesoblast (MSB.AX)
Stock Exchange: ASX
Ticker Codes: | MSB.AX | ASX:MSB |
Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions. The company's products under the Phase III clinical trials include MPC-150-IM for chronic and end-stage heart failure; MPC-06-ID for chronic low back pain; and MSC-100-IV for acute graft versus host disease in children. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, and diabetic kidney diseases and type 2 diabetes. The company has a collaboration agreement with JCR Pharmaceuticals Co., Ltd. It has operations in the United States, Australia, Singapore, and Switzerland. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.
|SMN Structural Monitoring Systems||0.98||4.8||47,285||0.05||NEUTRAL|
|SGF SG Fleet||2.68||4.7||164,520||0.08||NEUTRAL|
|PSQ Pacific Smiles||1.77||4.1||3,500||0.04||NEUTRAL|
|KAR Karoon Gas Australia||1.1||3.8||5,014,070||0.05||NEUTRAL|